Say Hello to TME-Empowered Patient Derived Tumoroids
The Most Physiologically Relevant Models Available
Say goodbye to PDX models and welcome PDTs. Through our Efficacy First model, we are transforming oncology research, therapeutic validation & precision medicine. Successes have already gone to Clinic!
Watch Below:
COMPASS Platform Video
We harness the powerful capabilities of Patient Derived Tumoroids (aka PDTs or Cancer Organoids with intact source TME) to accelerate the drug development process. We support ANY Drug Modality against ANY Solid Cancer Indication.
Our COMPASS platforms are uniquely empowered by our stable tumor models that are biobanked for rapid deployment and enabling reproducible studies.
We maintain an intact and functional tumor microenvironment (TME) for therapeutic discoverers and developers whose studies require robust and faithful preclinical research models. Our unique 3D tumor models enable the recapitulation of patient-specific tumor-immune interactions to fast-track the search for novel cures and bring hope to millions of patients.
Tumoroids are the perfectly optimized human tool for performing: